Welcome to the e-CCO Library Archive!
S. Sebastian1, K. Robinson2, L. Warren3, A. Marsh2, A. Wright2, F. Majeed3, H. Tsai1, A. Brooks2, M.E. McAlindon2, P.J. Hamlin3, A. Lobo2, 1Hull & East Yorkshire NHS Trust, Hull & York Medical School, United Kingdom, 2Sheffield Teaching Hospitals NHS Trust, United Kingdom, 3Leeds Teaching Hospitals NHS Trust, United Kingdom
Low uptake of cervical screening in immunosuppressed patients with Inflammatory Bowel Disease at a district general hospital
K. Wade*, H. Johnson, H. Dewhurst, S. Weaver, S. McLaughlin
Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom
Patient-reported symptom measures differ in their association with mucosal healing in adults with moderately to severely active ulcerative colitis: Results from ULTRA 1 and 2
J.-F. Colombel1, W.J. Sandborn2, W. Reinisch3, A.M. Robinson4, W. Wang4, B. Huang4, A. Lazar5, R. Thakkar4, 1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 2University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 3McMaster University, Department of Medicine, Hamilton, Canada, 4AbbVie Inc, GPRD, North Chicago, United States, 5AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany
E. Safroneeva1, S. Vavricka2, N. Fournier3, G. Rogler2, A. Straumann4, A. Schoepfer5, 1University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 2University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 3University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 4University Hospital Basel, Gastroenterology and Hepatology, Switzerland, 5University Hospital Lausanne / CHUV, Gastroenterology and Hepatology, Lausanne, Switzerland
Measles, Mumps and Rubella Seronegativity Rates in IBD Patients Commencing Biologic Therapy
R. Stack*1, 2, U. Kennedy1, D. Schmidt1, 2, M. Walshe1, 2, F. MacCarthy1, 2, N. Mahmud1, 2, S. McKiernan1, 2, D. Kevans1, 2
1St James's Hospital, Gastroenterology, Dublin, Ireland, 2Trinity College Dublin, School of Medicine, Dublin, Ireland
Pooled clinical trial analysis of MMX mesalazine safety: Focus on 4.8 g/d dose long-term exposure
S. Da Silva Sanchez1, M. Palmen2, P. Streck3, S. Inglis2, 1Shire, Medical Affairs, Brussels, Belgium, 2Shire, Clinical Development, Basingstoke, United Kingdom, 3Shire, Clinical Research & Development, Wayne, PA, United States
D. Wolf1, G. D'Haens2, W. Sandborn3, J.-F. Colombel4, G. Van Assche5, A. Lazar6, Q. Zhou7, A. Robinson7, J. Chao7, R. Thakkar7, 1Atlanta Gastroenterology Associates, Atlanta, United States, 2Academic Medical Center, Amsterdam, Netherlands, 3University of California San Diego, La Jolla, United States, 4Centre Hospitalier Universitaire de Lille, Lille, France, 5University of Toronto, Toronto, Canada, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7Abbott Laboratories, Abbott Park, United States
Prevalence of malnutrition in patients with Inflammatory Bowel Disease - a Romanian National Register based study
M. Ispas*1, A. Lupu1, L. Gheorghe1, D. Dobru2, A. Tantau3, A. Goldis4, M. Ilie5, C. Gheorghe1, M. Ciocirlan1, C. Cijevschi6, C. Mihai6, R. Iacob1, M. Diculescu1
1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Municipal Hospital Targu Mures, Gastroenterology, Targu Mures, Romania, 33rd Medical Clinic Cluj-Napoca, Gastroenterology, Cluj-Napoca, Romania, 4University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 5Floreasca Emergency Hospital, Gastroenterology, Bucharest, Romania, 6Gastroenterology and Hepatology Institute , Gastroenterology, Iasi, Romania
Perianal Crohn's disease – Experience of a tertiary referral center
S. Fernandes, P. Sousa, M. Moura, L. Correia, A. Rita Gonçalves, P. Moura Santos, A. Valente, C. Baldaia, J. Velosa, Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal
C. Praticò1, P. Gionchetti1, G. Spuri Fornarini1, A. Calafiore1, M. Campieri1, C. Calabrese1, F. Rizzello1, 1Bologna, Clinical Medicine, Bologna, Italy
Therapeutic adherence in patients with inflammatory bowel disease.
C. Azucena*, B. Nallely, Y.-F. Jesus
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico
Outcomes of surgical treatment of entero-urinary fistulas in Crohn's disease
I. Fernández-Blanco1, C. Taxonera2,3, G. Bastida4, V. García-Sánchez5, M. Gómez-García6, I. Marín-Jiménez7, E. Iglesias5, J.P. Gisbert8,9, M. Barreiro-de Acosta10, F. Bermejo11, M.J. Casanova8,9, C. Saro12, P. López-Serrano13, R. Plaza14, A. Algaba11, D. Olivares2,3, J.L. Mendoza2,3, 1Hospital Moncloa, Gastrointestinal Surgery, Madrid, Spain, 2H Clinico San Carlos, IdISSC, Madrid, Spain, 3H Clinico San Carlos, IBD Unit, Madrid, Spain, 4H La Fe, Service of Gastroenterology, Valencia, Spain, 5H Reina Sofía, Service of Gastroenterology, Córdoba, Spain, 6H Virgen de las Nieves, Service of Gastroenterology, Granada, Spain, 7H Gregorio Marañón, Service of Gastroenterology, Madrid, Spain, 8IP, CIBERehd, Madrid, Spain, 9H La Princesa, Gastroenterology Unit, Madrid, Spain, 10H Clinico de Santiago, Service of Gastroenterology, Santiago de Compostela, Spain, 11H Fuenlabrada, Service of Gastroenterology, Madrid, Spain, 12H de Cabueñes, Service of Gastroenterology, Gijón, Spain, 13H Alcorcón, Service of Gastroenterology, Madrid, Spain, 14H Infanta Leonor, Service of Gastroenterology, Madrid, Spain
V. Rodil1, M.L. De Castro2, V. Hernández3, J.R. Pineda3, S. Pereira3, J. Martínez Cadilla3, P. Estévez3, L. Cid3, D. Martínez-Ares3, L. Sanromán3, V. Del Campo4, J.I. Rodríguez Prada3, 1Universitary Hospital, Internal Medicine, Vigo, Spain, 2Universitary Hospital, Gastroenterology, Vigo, Spain, 3Universitary Hospital, Gastroenterology, Vigo, Spain, 4Universitary Hospital, Epidemiology, Vigo, Spain
Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease
K.-C. Wu*1, Z.H. Ran2, X. Gao3, M. Chen4, J. Zhong5, J.-Q. Sheng6, M.A. Kamm7, 8, S. Travis9, A.M. Robinson10, K. Wallace10, M. Shapiro10, Y. Li10, R.B. Thakkar10
1Xijing Hospital of the Fourth Military Medical University, Gastroenterology, Xi’an, China, 2Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 3The Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 4The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 5Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 6The Military General Hospital of Beijing, PLA, Gastroenterology, Beijing, China, 7St. Vincent’s Hospital, Gastroenterology, Melbourne, Australia, 8The University of Melbourne, Gastroenterology, Parkville, Australia, 9Translational Gastroenterology Unit, Gastroenterology, Oxford, United Kingdom, 10AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States
Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease
M. Sako, T. Kawaguchi, A. Hirayama, G. Fukushi, K. Hayama, T. Fujiwara, N. Yoshimura, M. Takazoe, Social Insurance Central Hospital, Centre for Inflammatory Bowel Disease, Tokyo, Japan